“The FDA approval to begin the Bivacor Total Artificial Heart EFS is a critical milestone for Bivacor and is another validation of the remarkable work and accomplishments of the entire Bivacor team. This device will provide a unique approach to help patients currently with limited clinical options,” said William Cohn, heart surgeon at the Texas Heart Institute and Bivacor chief medical officer.
BiVACOR, Inc., a pioneer in the development of total artificial hearts, has achieved a significant milestone with the US Food and Drug Administration (FDA).
HUNTINGTON BEACH, Calif. & GOLD COAST, Australia & HOUSTON (BUSINESS WIRE) BiVACOR, Inc., a clinical-stage medical device company developing a total artificial heart (TAH), today announced the
Ventricular assist devices market size was valued at $1,338.53 million in 2021, and is projected to reach $2,880.66 million by 2031, growing at a CAGR of 7.9% from 2022 to 2031. Ventricular assist devices market analysis provided from 2021 to 2031 to identify the prevailing market opportunities. Major factors that d.